BMB seminar: Beta-cell replacement for insulin-dependent diabetes mellitus

Dr. Hanne Scholz, group leader Experimental cell transplantation, Department of Transplantation Medicine, Oslo University Hospital

Foto: OUS

Type 1 diabetes (T1D) is an autoimmune disease caused by progressive
destruction of the beta cells in the pancreas. Treatment option that
targeting beta cell function and/or the beta cell mass is highly
wanting. Standard of care in T1D is life-long therapy with exogenous
insulin. In spite of optimal insulin therapy (including digital insulin
pump devices and subcutaneous glucose sensors), periods of hyperglycemia
induce serious vascular- and neurological complications such as
accelerated arteriosclerosis, kidney failure and impaired vision.
A milestone in cell-based therapies for diabetes has been achieved with
the application of islet transplantation isolated from deceased donors
that offering to restore endogenous insulin production to patients
suffering from severe diabetes, but long term results show deteriorating
islet function over time due to multifactorial factors such as graft
rejection, immunosuppression-associated complications ad finally lack of
donor organs. Treatment option that targeting beta cell function and/or
the beta cell mass is therefore highly needed.

Published Apr. 13, 2018 2:59 PM - Last modified Apr. 13, 2018 2:59 PM